Here’s something I’ve seen time and again: the companies that rise above the noise aren’t always the ones with the biggest facilities or the largest teams. They’re the ones that know how to leverage their intellectual property — their brands, strains, technologies, and formulations — through licensing.
Take Canopy Growth, for example. When they partnered with Constellation Brands in that $4 billion deal, the real driver wasn’t just cultivation. It was the ability to license IP — like cannabis-infused beverage formulations — and scale into new markets quickly. That’s the power of licensing.
Why Licensing Should Be on Your Radar
The cannabis industry is evolving rapidly, with competition coming from every angle. Licensing gives you the tools to protect what you’ve built and grow without overextending.
Aurora Cannabis understood this when it licensed out its production technology instead of building new facilities. That strategy expanded its footprint without the capital burden. GW Pharmaceuticals is another example. They built a fortress of patents around cannabis-derived drug formulations and licensed commercialization rights globally. That approach ultimately made them so valuable that Jazz Pharmaceuticals acquired them for $7.2 billion.
Licensing isn’t just about protecting your assets — it’s about unlocking growth.
What Licensing Looks Like in Cannabis
Licensing isn’t one-size-fits-all. There are several models cannabis companies use to scale.
Cookies is a standout case. By licensing its brand and retail model to trusted operators in different states, Cookies grew into a national presence while keeping quality and compliance firmly in check. Tilray followed a different path. Instead of becoming brewers, they partnered with Anheuser-Busch InBev, co-developing cannabis beverages. That deal opened an entirely new category without the risk of building from scratch.
Whether you’re licensing your brand, technology, or genetics, the right strategy lets you expand faster and smarter.
The Deal Terms That Really Matter
Because cannabis operates in such a heavily regulated environment, licensing agreements must be carefully drafted. Territory is one of the first issues to nail down. MedMen’s deal with Cronos, for instance, carved out precise jurisdictional rights to stay compliant.
Exclusivity is another key factor. Canopy Growth has often locked in exclusive rights within categories like beverages to protect market share. Then there’s quality control. Cookies is meticulous here, requiring licensees to follow detailed SOPs for cultivation, packaging, and branding to ensure consistency.
The bottom line: in cannabis licensing, terms are more than legal language — they’re risk management.
How Royalties Work in Cannabis Deals
Royalty structures in cannabis take many forms. Most brand licensing deals fall in the 5–10% of net sales range. Some companies layer in tiered royalties, where rates climb once sales pass certain milestones. Tilray’s beverage partnerships, for example, included revenue thresholds tied to performance.
Many deals also require minimum guarantees to ensure predictable income. Charlotte’s Web has relied on this model for its CBD licensing arrangements. In other cases, especially for devices, royalties are structured per unit. PAX Labs, for instance, often uses per-cartridge royalties for its vaporizer IP.
A well-structured royalty agreement doesn’t just generate income — it demonstrates stability to investors.
Managing Partners in a Regulated Market
“Set it and forget it” doesn’t work in cannabis. Regulations shift constantly, and every state has its own framework. Companies like Curaleaf manage this by writing compliance triggers directly into their contracts, giving them the right to audit or terminate deals if a partner loses their license.
Cookies takes a proactive approach, providing training, marketing support, and compliance updates to its licensees. This hands-on management ensures its brand remains strong across markets.
If your partners stumble, your reputation suffers. Oversight isn’t optional — it’s essential.
How Licensing Positions You for Exit
Licensing isn’t just about near-term growth. It’s one of the smartest ways to prepare for acquisition or outside investment.
Buyers and investors prize recurring revenue. They also look for companies with enforceable licensing agreements already in place. GW Pharma’s acquisition by Jazz is the perfect example: licensing made its IP immediately monetizable and attractive at scale.
By building licensing into your strategy now, you position your business as a high-value acquisition target later.
Working Around Federal Restrictions
The federal patchwork in the U.S. can feel like a roadblock, but licensing offers clear paths forward. Many companies expand state by state, licensing their brands to local operators. Others, like Tilray and Canopy, have pursued international deals where cannabis is federally legal, giving them a head start in Europe and beyond.
Ancillary products like vaporizers, accessories, or CBD wellness items also fall outside of federal cannabis restrictions, making them prime candidates for licensing.
With the right structure, federal illegality becomes a challenge to navigate — not a dead end.
The Cannabis Licensing Market Is Heating Up
The global cannabis market is projected to surpass $70 billion by 2030. Licensing is already driving this growth, especially in cross-industry deals with beverage, food, and wellness companies. IP filings are climbing in formulations, genetics, and devices, signaling where future value will lie.
Investors are starting to place higher valuations on companies with licensing frameworks in place. In cannabis, licensing is shifting from an optional strategy to the cornerstone of sustainable growth.
How Licensing Consulting Group Helps Cannabis Companies
At Licensing Consulting Group (LCG), we specialize in helping companies maximize the value of their IP through licensing.
We start by uncovering your most valuable assets — whether it’s your genetics, formulations, or brand identity. Then we design deal structures tailored to cannabis, covering compliance clauses, royalty protections, and strategies to expand across multiple states and international markets.
We also help you negotiate terms that ensure predictable revenue, from minimum guarantees to tiered royalties, while guiding you on how to manage licensees in a regulated market. Most importantly, we position your licensing program to attract investors or acquirers, making your business more valuable in the long run.
Ready to unlock the full value of your cannabis IP? Schedule a consultation today and let’s explore your licensing opportunities.
Free E-book: Cannabis Licensing Case Study Pack
Discover how leading cannabis companies used licensing to expand, attract investors, and maximize revenue. Click here to get this e-book.
Rand Brenner is an IP professional whose passion is helping inventors, startups, and businesses use licensing to turn their IP into income-producing products, services, and technologies. His decades of experience run the gamut from medical devices to food technology to consumer products. He’s licensed some of the biggest Hollywood entertainment blockbusters, including the Batman Movies (1 and 2) and the number one kid’s action TV show, the Mighty Morphin Power Rangers. Rand speaks about licensing and is a featured speaker at investment conferences, trade shows, colleges, and startup events. His first book, Hidden Wealth: The Money-Making Power of Licensing, was released in 2019 and is available on Amazon.com. He’s also a published writer, and his articles have appeared in several prestigious trade magazines, including The Licensing Journal, Intellectual Property Magazine, and License India.
Working Through a Licensing or Commercialization Challenge?
If you have market-ready intellectual property, a licensing campaign that has stalled, or a business opportunity that may benefit from licensing, a short strategy discussion can help clarify the next step.